JP2017193592A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017193592A5 JP2017193592A5 JP2017151559A JP2017151559A JP2017193592A5 JP 2017193592 A5 JP2017193592 A5 JP 2017193592A5 JP 2017151559 A JP2017151559 A JP 2017151559A JP 2017151559 A JP2017151559 A JP 2017151559A JP 2017193592 A5 JP2017193592 A5 JP 2017193592A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclopropyl
- thiazol
- triazol
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 C 1 -C 6 carbonyl Chemical group 0.000 claims 75
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 239000001257 hydrogen Substances 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 15
- 229910052757 nitrogen Inorganic materials 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 9
- 125000002619 bicyclic group Chemical group 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 239000001301 oxygen Substances 0.000 claims 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000002950 monocyclic group Chemical group 0.000 claims 6
- 125000006001 difluoroethyl group Chemical group 0.000 claims 5
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 5
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 5
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 claims 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 claims 4
- 125000001246 bromo group Chemical group Br* 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 201000002793 renal fibrosis Diseases 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 125000005816 fluoropropyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])* 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- RHBNPXMMGYHEMX-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]-5-(1,4-oxazepan-4-yl)pyridine-2-carboxamide Chemical compound C1(CC1)C=1N=CN(C1)C1=CC(=NC=C1N1CCOCCC1)C(=O)NC=1N=C(SC1)C1=NN=CN1C1CC1 RHBNPXMMGYHEMX-UHFFFAOYSA-N 0.000 claims 1
- MLKBIPNUPIWFRD-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]-5-(2-oxa-7-azaspiro[3.5]nonan-7-yl)pyridine-2-carboxamide Chemical compound C1(CC1)C=1N=CN(C1)C1=CC(=NC=C1N1CCC2(COC2)CC1)C(=O)NC=1N=C(SC1)C1=NN=CN1C1CC1 MLKBIPNUPIWFRD-UHFFFAOYSA-N 0.000 claims 1
- VWVSGSNEMFMEAE-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]-5-(3,3-difluoroazetidin-1-yl)pyridine-2-carboxamide Chemical compound C1(CC1)C=1N=CN(C1)C1=CC(=NC=C1N1CC(C1)(F)F)C(=O)NC=1N=C(SC1)C1=NN=CN1C1CC1 VWVSGSNEMFMEAE-UHFFFAOYSA-N 0.000 claims 1
- UNYRWSBHWKLEPE-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]-5-(3-methoxy-3-methylazetidin-1-yl)pyridine-2-carboxamide Chemical compound C1(CC1)C=1N=CN(C1)C1=CC(=NC=C1N1CC(C1)(C)OC)C(=O)NC=1N=C(SC1)C1=NN=CN1C1CC1 UNYRWSBHWKLEPE-UHFFFAOYSA-N 0.000 claims 1
- RMDQTUKUWQKGFZ-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]-5-(3-methoxypyrrolidin-1-yl)pyridine-2-carboxamide Chemical compound C1(CC1)C=1N=CN(C1)C1=CC(=NC=C1N1CC(CC1)OC)C(=O)NC=1N=C(SC1)C1=NN=CN1C1CC1 RMDQTUKUWQKGFZ-UHFFFAOYSA-N 0.000 claims 1
- LMCHECNDQKZNCD-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]-5-(3-morpholin-4-ylazetidin-1-yl)pyridine-2-carboxamide Chemical compound C1(CC1)C=1N=CN(C1)C1=CC(=NC=C1N1CC(C1)N1CCOCC1)C(=O)NC=1N=C(SC1)C1=NN=CN1C1CC1 LMCHECNDQKZNCD-UHFFFAOYSA-N 0.000 claims 1
- AFELNRHIXXVTNY-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]-5-(3-oxo-5,6,8,8a-tetrahydro-1H-[1,3]oxazolo[3,4-a]pyrazin-7-yl)pyridine-2-carboxamide Chemical compound C1(CC1)C=1N=CN(C1)C1=CC(=NC=C1N1CC2N(CC1)C(OC2)=O)C(=O)NC=2N=C(SC2)C2=NN=CN2C2CC2 AFELNRHIXXVTNY-UHFFFAOYSA-N 0.000 claims 1
- GMPZDJRNJKFIAT-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]-5-(4-fluoropiperidin-1-yl)pyridine-2-carboxamide Chemical compound C1(CC1)C=1N=CN(C1)C1=CC(=NC=C1N1CCC(CC1)F)C(=O)NC=1N=C(SC1)C1=NN=CN1C1CC1 GMPZDJRNJKFIAT-UHFFFAOYSA-N 0.000 claims 1
- GTMDADVBDVQONE-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]-5-(4-methoxy-4-methylpiperidin-1-yl)pyridine-2-carboxamide Chemical compound C1(CC1)C=1N=CN(C1)C1=CC(=NC=C1N1CCC(CC1)(C)OC)C(=O)NC=1N=C(SC1)C1=NN=CN1C1CC1 GTMDADVBDVQONE-UHFFFAOYSA-N 0.000 claims 1
- NHHMVQGTXMGSAE-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]-5-(4-methoxypiperidin-1-yl)pyridine-2-carboxamide Chemical compound C1(CC1)C=1N=CN(C1)C1=CC(=NC=C1N1CCC(CC1)OC)C(=O)NC=1N=C(SC1)C1=NN=CN1C1CC1 NHHMVQGTXMGSAE-UHFFFAOYSA-N 0.000 claims 1
- LCFPCLKTQXMUGV-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]-5-[3-(difluoromethyl)azetidin-1-yl]pyridine-2-carboxamide Chemical compound C1(CC1)C=1N=CN(C1)C1=CC(=NC=C1N1CC(C1)C(F)F)C(=O)NC=1N=C(SC1)C1=NN=CN1C1CC1 LCFPCLKTQXMUGV-UHFFFAOYSA-N 0.000 claims 1
- VOMQQXSMYIYUPK-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]-5-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]pyridine-2-carboxamide Chemical compound C1(CC1)C=1N=CN(C1)C1=CC(=NC=C1N1CCN(CC1)CC(F)(F)F)C(=O)NC=1N=C(SC1)C1=NN=CN1C1CC1 VOMQQXSMYIYUPK-UHFFFAOYSA-N 0.000 claims 1
- DURJLTKEXQILNU-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]-5-[4-(trifluoromethyl)piperidin-1-yl]pyridine-2-carboxamide Chemical compound C1(CC1)C=1N=CN(C1)C1=CC(=NC=C1N1CCC(CC1)C(F)(F)F)C(=O)NC=1N=C(SC1)C1=NN=CN1C1CC1 DURJLTKEXQILNU-UHFFFAOYSA-N 0.000 claims 1
- HOYJVUGIPWXZQG-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]-5-[4-(methylcarbamoyl)piperidin-1-yl]pyridine-2-carboxamide Chemical compound C1CC(C(=O)NC)CCN1C1=CN=C(C(=O)NC=2N=C(SC=2)C=2N(C=NN=2)C2CC2)C=C1N1C=C(C2CC2)N=C1 HOYJVUGIPWXZQG-UHFFFAOYSA-N 0.000 claims 1
- BMHJVMAHIYFSOF-UHFFFAOYSA-N 4-cyclopropyl-1,2,4-triazole Chemical compound C1CC1N1C=NN=C1 BMHJVMAHIYFSOF-UHFFFAOYSA-N 0.000 claims 1
- UZZFEAONZIHMSX-UHFFFAOYSA-N 5-(3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl)-4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]pyridine-2-carboxamide Chemical compound C1C2N(CCN1C=1C(=CC(=NC1)C(=O)NC=1N=C(SC1)C1=NN=CN1C1CC1)N1C=NC(=C1)C1CC1)CCC2 UZZFEAONZIHMSX-UHFFFAOYSA-N 0.000 claims 1
- UTWWORAHCAYQGO-UHFFFAOYSA-N 5-(3-cyanoazetidin-1-yl)-4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]pyridine-2-carboxamide Chemical compound C(#N)C1CN(C1)C=1C(=CC(=NC1)C(=O)NC=1N=C(SC1)C1=NN=CN1C1CC1)N1C=NC(=C1)C1CC1 UTWWORAHCAYQGO-UHFFFAOYSA-N 0.000 claims 1
- IGIYTPHNJWHEHH-UHFFFAOYSA-N 5-(4-cyanopiperidin-1-yl)-4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]pyridine-2-carboxamide Chemical compound C(#N)C1CCN(CC1)C=1C(=CC(=NC1)C(=O)NC=1N=C(SC1)C1=NN=CN1C1CC1)N1C=NC(=C1)C1CC1 IGIYTPHNJWHEHH-UHFFFAOYSA-N 0.000 claims 1
- 208000030090 Acute Disease Diseases 0.000 claims 1
- WEMKKBMCJKSRPD-OYMFQORVSA-N C[C@@H](C(F)(F)F)N1C=NN=C1C2=NC(=CS2)N(C(=O)C3=CC=CC=N3)N4CC5CCCN5C(C4)N6C=C(N=C6)C7CC7 Chemical compound C[C@@H](C(F)(F)F)N1C=NN=C1C2=NC(=CS2)N(C(=O)C3=CC=CC=N3)N4CC5CCCN5C(C4)N6C=C(N=C6)C7CC7 WEMKKBMCJKSRPD-OYMFQORVSA-N 0.000 claims 1
- DGIBKCUWFLFJRY-UHFFFAOYSA-N N-[2-[4-(1,1,1-trifluoropropan-2-yl)-1,2,4-triazol-3-yl]-1,3-thiazol-4-yl]pyridine-2-carboxamide Chemical compound FC(C(C)N1C(=NN=C1)C=1SC=C(N=1)NC(C1=NC=CC=C1)=O)(F)F DGIBKCUWFLFJRY-UHFFFAOYSA-N 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000006419 fluorocyclopropyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361918784P | 2013-12-20 | 2013-12-20 | |
| US61/918,784 | 2013-12-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540662A Division JP2016540029A (ja) | 2013-12-20 | 2014-12-15 | アポトーシスシグナル調節キナーゼ阻害剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019013185A Division JP2019077719A (ja) | 2013-12-20 | 2019-01-29 | アポトーシスシグナル調節キナーゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017193592A JP2017193592A (ja) | 2017-10-26 |
| JP2017193592A5 true JP2017193592A5 (enExample) | 2017-12-07 |
| JP6509968B2 JP6509968B2 (ja) | 2019-05-08 |
Family
ID=52282961
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540662A Withdrawn JP2016540029A (ja) | 2013-12-20 | 2014-12-15 | アポトーシスシグナル調節キナーゼ阻害剤 |
| JP2017151559A Expired - Fee Related JP6509968B2 (ja) | 2013-12-20 | 2017-08-04 | アポトーシスシグナル調節キナーゼ阻害剤 |
| JP2019013185A Pending JP2019077719A (ja) | 2013-12-20 | 2019-01-29 | アポトーシスシグナル調節キナーゼ阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540662A Withdrawn JP2016540029A (ja) | 2013-12-20 | 2014-12-15 | アポトーシスシグナル調節キナーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019013185A Pending JP2019077719A (ja) | 2013-12-20 | 2019-01-29 | アポトーシスシグナル調節キナーゼ阻害剤 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9169243B2 (enExample) |
| EP (1) | EP3083615B1 (enExample) |
| JP (3) | JP2016540029A (enExample) |
| KR (1) | KR20160098463A (enExample) |
| CN (1) | CN105980382A (enExample) |
| AP (1) | AP2016009248A0 (enExample) |
| AU (1) | AU2014366235B2 (enExample) |
| CA (1) | CA2934454C (enExample) |
| CL (1) | CL2016001538A1 (enExample) |
| CR (1) | CR20160268A (enExample) |
| CU (1) | CU20160095A7 (enExample) |
| DO (1) | DOP2016000136A (enExample) |
| EA (1) | EA201690973A1 (enExample) |
| ES (1) | ES2731703T3 (enExample) |
| HK (1) | HK1226073A1 (enExample) |
| IL (1) | IL245807A0 (enExample) |
| MD (1) | MD4658B1 (enExample) |
| MX (1) | MX2016008254A (enExample) |
| NZ (1) | NZ720660A (enExample) |
| PE (1) | PE20160859A1 (enExample) |
| PH (1) | PH12016501149A1 (enExample) |
| SG (1) | SG11201604473VA (enExample) |
| WO (1) | WO2015095059A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI598347B (zh) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| MX2012015105A (es) * | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Inhibidores de cinasa de regulacion mediante señal de apoptosis. |
| UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
| EP3152198B1 (en) * | 2014-06-09 | 2019-02-27 | Takeda Pharmaceutical Company Limited | Radiolabeled compounds |
| CN110036005B (zh) * | 2016-11-16 | 2022-09-27 | 广东东阳光药业有限公司 | 酰胺衍生物及其在药物中的应用 |
| WO2018094964A1 (zh) * | 2016-11-25 | 2018-05-31 | 武汉大学 | 一种以凋亡信号调节激酶1n端二聚化为靶点筛选用于治疗脂肪性肝炎药物的方法 |
| US20180325931A1 (en) | 2017-01-21 | 2018-11-15 | Ningbo Zhiming Biotechnology Co., Ltd. | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome |
| CN109071538B (zh) * | 2017-01-22 | 2020-03-17 | 福建广生堂药业股份有限公司 | 作为ask1抑制剂的吡啶衍生物及其制备方法和应用 |
| EP3590931A4 (en) * | 2017-03-03 | 2020-11-18 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | AMIDE DERIVATIVE INHIBITOR, PROCESS OF PREPARATION AND APPLICATION |
| JP7377718B2 (ja) | 2017-05-12 | 2023-11-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | アポトーシスシグナル調節キナーゼ１阻害剤およびその使用方法 |
| US10450301B2 (en) | 2017-05-25 | 2019-10-22 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2018218044A2 (en) | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals Inc | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2018218042A1 (en) | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10597382B2 (en) | 2017-08-28 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CN109232538B (zh) * | 2017-10-12 | 2020-07-24 | 深圳市塔吉瑞生物医药有限公司 | 一种1,2,4-三氮唑类化合物 |
| US11434249B1 (en) | 2018-01-02 | 2022-09-06 | Seal Rock Therapeutics, Inc. | ASK1 inhibitor compounds and uses thereof |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| KR102798464B1 (ko) * | 2018-05-02 | 2025-04-21 | 이난타 파마슈티칼스, 인코포레이티드 | 아폽토시스 신호 조절 키나제 1 억제제를 포함하는 테트라졸 및 이의 사용 방법 |
| WO2019213239A1 (en) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| JP2021528456A (ja) * | 2018-06-27 | 2021-10-21 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ａｓｋ１阻害剤 |
| US10968199B2 (en) | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11345699B2 (en) | 2018-11-19 | 2022-05-31 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020198214A1 (en) | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012015105A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Inhibidores de cinasa de regulacion mediante señal de apoptosis. |
| UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
-
2014
- 2014-12-15 CR CR20160268A patent/CR20160268A/es unknown
- 2014-12-15 SG SG11201604473VA patent/SG11201604473VA/en unknown
- 2014-12-15 EA EA201690973A patent/EA201690973A1/ru unknown
- 2014-12-15 AP AP2016009248A patent/AP2016009248A0/en unknown
- 2014-12-15 JP JP2016540662A patent/JP2016540029A/ja not_active Withdrawn
- 2014-12-15 CN CN201480069141.7A patent/CN105980382A/zh active Pending
- 2014-12-15 EP EP14824288.6A patent/EP3083615B1/en active Active
- 2014-12-15 AU AU2014366235A patent/AU2014366235B2/en not_active Ceased
- 2014-12-15 KR KR1020167019208A patent/KR20160098463A/ko not_active Withdrawn
- 2014-12-15 PE PE2016000806A patent/PE20160859A1/es not_active Application Discontinuation
- 2014-12-15 MD MD20160069A patent/MD4658B1/ro not_active IP Right Cessation
- 2014-12-15 US US14/570,655 patent/US9169243B2/en active Active
- 2014-12-15 WO PCT/US2014/070362 patent/WO2015095059A1/en not_active Ceased
- 2014-12-15 MX MX2016008254A patent/MX2016008254A/es unknown
- 2014-12-15 NZ NZ720660A patent/NZ720660A/en not_active IP Right Cessation
- 2014-12-15 US US15/105,372 patent/US9908875B2/en active Active
- 2014-12-15 HK HK16114514.0A patent/HK1226073A1/zh unknown
- 2014-12-15 CA CA2934454A patent/CA2934454C/en not_active Expired - Fee Related
- 2014-12-15 ES ES14824288T patent/ES2731703T3/es active Active
-
2016
- 2016-05-24 IL IL245807A patent/IL245807A0/en unknown
- 2016-06-14 DO DO2016000136A patent/DOP2016000136A/es unknown
- 2016-06-14 PH PH12016501149A patent/PH12016501149A1/en unknown
- 2016-06-16 CL CL2016001538A patent/CL2016001538A1/es unknown
- 2016-06-20 CU CUP2016000095A patent/CU20160095A7/es unknown
-
2017
- 2017-08-04 JP JP2017151559A patent/JP6509968B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-29 JP JP2019013185A patent/JP2019077719A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017193592A5 (enExample) | ||
| US11795164B2 (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| US11207325B2 (en) | Triazolopyrimidine compounds and uses thereof | |
| AU2014291711B2 (en) | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | |
| JP2020530446A5 (enExample) | ||
| CN105339370B (zh) | 用于治疗炎症性疾病的化合物和及其药物组合物 | |
| US9150568B2 (en) | Compositions and methods for modulating FXR | |
| ES2727376T3 (es) | Derivados de aminotriazina útiles como compuestos inhibidores de quinasa de unión TANK | |
| JP2014525444A5 (enExample) | ||
| RU2013145299A (ru) | Тиазолопиримидины | |
| KR102927636B1 (ko) | 파르네소이드 x 수용체 조정제로서의 치환된 비시클릭 화합물 | |
| JP2016523911A5 (enExample) | ||
| JP2010513283A (ja) | 新規なオキサジアゾール化合物 | |
| JP2017511365A5 (enExample) | ||
| HRP20230789T1 (hr) | Derivati benzhidroksamske kiseline kao selektivni inhibitori hdac6 | |
| JP2011523945A5 (enExample) | ||
| JP2012532931A5 (enExample) | ||
| JP2017508766A5 (enExample) | ||
| JP2020516671A5 (enExample) | ||
| JP2016507551A5 (enExample) | ||
| JP2020526549A5 (enExample) | ||
| EP4514790A1 (en) | Compounds for inhibiting kif18a | |
| JP2016518344A5 (enExample) | ||
| HRP20231306T1 (hr) | Terapeutski spojevi | |
| RU2017120855A (ru) | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина |